Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients
暂无分享,去创建一个
Yu-Hong Chen | Yu Wang | Xiao-hui Zhang | Lanping Xu | Xiao-jun Huang | W. Han | Yao Chen | Huan Chen | Kai-yan Liu | Feng‐rong Wang | Jing‐zhi Wang | Chen‐hua Yan
[1] Yu-Hong Chen,et al. High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation , 2016, European journal of haematology.
[2] A. Nagler,et al. Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] Yu-Hong Chen,et al. Infusion‐related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graft‐versus‐host disease , 2015, Pediatric transplantation.
[4] Yanrong Liu. [The guidelines for absolute count of CD34⁺ cell determination by flow cytometry]. , 2015, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
[5] Yu Wang,et al. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation]. , 2014, Zhonghua nei ke za zhi.
[6] Yu-Hong Chen,et al. Who is the best donor for a related HLA haplotype-mismatched transplant? , 2014, Blood.
[7] C. Cancrini,et al. HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. , 2014, Blood.
[8] L. Xu,et al. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances , 2014, Bone Marrow Transplantation.
[9] F. Corbella,et al. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] R. Porcher,et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors , 2014, Haematologica.
[11] W. Jia,et al. [Unbearable weight of being: talk about losing weight]. , 2014, Zhonghua nei ke za zhi.
[12] Yu-Hong Chen,et al. The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLA‐mismatched/haploidentical hematopoietic stem cell transplantation , 2011, Pediatric blood & cancer.
[13] Asha B. Pillai,et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. , 2011, Blood.
[14] Monika Mielcarek,et al. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] J. Klein,et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. , 2009, Blood.
[16] Yu-Hong Chen,et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] Yu Wang,et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] L. Xu,et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT , 2009, Bone Marrow Transplantation.
[19] David D. Smith,et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] Q. Jiang,et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] S. Grupp,et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. , 2007, Blood.
[22] P. Albert,et al. Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. , 2007, Biology of Blood and Marrow Transplantation.
[23] M. Ostronoff,et al. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] Yu-Hong Chen,et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.
[25] C. Mecucci,et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Gale,et al. Decreased treatment failure in recipients of HLA‐identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses , 2003, British journal of haematology.
[27] J. Bourhis,et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation , 2003, Leukemia.
[28] Â. Maiolino,et al. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria , 2003, Bone Marrow Transplantation.
[29] L. Allen. Stem cells. , 2003, The New England journal of medicine.
[30] N. Schmitz,et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. , 2002, Blood.
[31] S. Chevret,et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. , 2002, Blood.
[32] S. Heimfeld,et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. , 2001, Blood.
[33] C. Hutchins,et al. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. , 2001, Blood.
[34] E. Montserrat,et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? , 2001, Blood.
[35] Yan-rong Liu,et al. [Standardization and Quality Control in Flow Cytometric Enumeration of CD34(+) cells] , 2000, Zhongguo shi yan xue ye xue za zhi.
[36] S. Singhal,et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? , 2000, Bone Marrow Transplantation.
[37] V. Najfeld,et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF , 1997, Bone Marrow Transplantation.
[38] C. Dunbar,et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. , 1996, Blood.
[39] R. Storb,et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation , 1994, British journal of haematology.
[40] K. Sullivan,et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.
[41] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.